The Genomic Landscape of Chronic Lymphocytic Leukemia: Clinical Implications

Overview

Journal BMC Med

Publisher Biomed Central

Specialty General Medicine

Date 2013 May 10

PMID 23656622

Citations 20

Authors

Victor Quesada

Andrew J Ramsay

David Rodriguez

Xose S Puente

Elias Campo

Carlos Lopez-Otin

Affiliations

Soon will be listed here.

Abstract

A precise understanding of the genomic and epigenomic features of chronic lymphocytic leukemia (CLL) may benefit the study of the disease's staging and treatment. While recent reports have shed some light on these aspects, several challenges need to be addressed before translating this research into clinical practice. Thus, even the best candidate driver genes display low mutational rates compared to other tumors. This means that a large percentage of cases do not display clear tumor-driving point mutations, or show candidate driving point mutations with no obvious biochemical relationship to the more frequently mutated genes. This genomic landscape probably reflects either an unknown underlying biochemical mechanism playing a key role in CLL or multiple biochemical pathways independently driving the development of this tumor. The elucidation of either scenario will have important consequences on the clinical management of CLL. Herein, we review the recent advances in the definition of the genomic landscape of CLL and the ongoing research to characterize the underlying biochemical events that drive this disease.

Citing Articles

MALAT1 expression is associated with aggressive behavior in indolent B-cell neoplasms.

Fernandez-Garnacho E, Nadeu F, Martin S, Mozas P, Rivero A, Delgado J Sci Rep. 2023; 13(1):16839.

PMID: 37803049 PMC: 10558466. DOI: 10.1038/s41598-023-44174-8.

Nucleosome repositioning in chronic lymphocytic leukemia.

Piroeva K, McDonald C, Xanthopoulos C, Fox C, Clarkson C, Mallm J Genome Res. 2023; 33(10):1649-1661.

PMID: 37699659 PMC: 10691546. DOI: 10.1101/gr.277298.122.

mutation-mediated sensitization to H3B-8800 splicing inhibitor in chronic lymphocytic leukemia.

Lopez-Oreja I, Gohr A, Playa-Albinyana H, Giro A, Arenas F, Higashi M Life Sci Alliance. 2023; 6(11).

PMID: 37562845 PMC: 10415613. DOI: 10.26508/lsa.202301955.

The spectrum of subclonal TP53 mutations in chronic lymphocytic leukemia: A next generation sequencing retrospective study.

De Luca G, Cerruti G, Lastraioli S, Conte R, Ibatici A, Di Felice N Hematol Oncol. 2022; 40(5):962-975.

PMID: 35961859 PMC: 10086786. DOI: 10.1002/hon.3063.

Multi-omics reveals clinically relevant proliferative drive associated with mTOR-MYC-OXPHOS activity in chronic lymphocytic leukemia.

Lu J, Cannizzaro E, Meier-Abt F, Scheinost S, Bruch P, Giles H Nat Cancer. 2021; 2(8):853-864.

PMID: 34423310 PMC: 7611543. DOI: 10.1038/s43018-021-00216-6.

References

Rozovski U, Keating M, Estrov Z . The significance of spliceosome mutations in chronic lymphocytic leukemia. Leuk Lymphoma. 2012; 54(7):1364-6. PMC: 4176818. DOI: 10.3109/10428194.2012.742528. View

Rossi D, Rasi S, Fabbri G, Spina V, Fangazio M, Forconi F . Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood. 2011; 119(2):521-9. PMC: 3257017. DOI: 10.1182/blood-2011-09-379966. View

Visconte V, Makishima H, Maciejewski J, Tiu R . Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders. Leukemia. 2012; 26(12):2447-54. PMC: 3645466. DOI: 10.1038/leu.2012.130. View

Rossi D, Fangazio M, Rasi S, Vaisitti T, Monti S, Cresta S . Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood. 2012; 119(12):2854-62. DOI: 10.1182/blood-2011-12-395673. View

Meyerson M, Gabriel S, Getz G . Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet. 2010; 11(10):685-96. DOI: 10.1038/nrg2841. View

Puente X, Lopez-Otin C . The evolutionary biography of chronic lymphocytic leukemia. Nat Genet. 2013; 45(3):229-31. DOI: 10.1038/ng.2556. View

Greenman C, Stephens P, Smith R, Dalgliesh G, Hunter C, Bignell G . Patterns of somatic mutation in human cancer genomes. Nature. 2007; 446(7132):153-8. PMC: 2712719. DOI: 10.1038/nature05610. View

Sportoletti P, Baldoni S, Cavalli L, Del Papa B, Bonifacio E, Ciurnelli R . NOTCH1 PEST domain mutation is an adverse prognostic factor in B-CLL. Br J Haematol. 2010; 151(4):404-6. DOI: 10.1111/j.1365-2141.2010.08368.x. View

Stilgenbauer S, Schnaiter A, Paschka P, Zenz T, Rossi M, Dohner K . Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood. 2014; 123(21):3247-54. DOI: 10.1182/blood-2014-01-546150. View

10.

Wang L, Lawrence M, Wan Y, Stojanov P, Sougnez C, Stevenson K . SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011; 365(26):2497-506. PMC: 3685413. DOI: 10.1056/NEJMoa1109016. View

11.

Gonzalez D, Martinez P, Wade R, Hockley S, Oscier D, Matutes E . Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol. 2011; 29(16):2223-9. DOI: 10.1200/JCO.2010.32.0838. View

12.

Beckman R, Schemmann G, Yeang C . Impact of genetic dynamics and single-cell heterogeneity on development of nonstandard personalized medicine strategies for cancer. Proc Natl Acad Sci U S A. 2012; 109(36):14586-91. PMC: 3437850. DOI: 10.1073/pnas.1203559109. View

13.

Ramsay A, Martinez-Trillos A, Jares P, Rodriguez D, Kwarciak A, Quesada V . Next-generation sequencing reveals the secrets of the chronic lymphocytic leukemia genome. Clin Transl Oncol. 2012; 15(1):3-8. DOI: 10.1007/s12094-012-0922-z. View

14.

Ter Brugge P, Ta V, de Bruijn M, Keijzers G, Maas A, van Gent D . A mouse model for chronic lymphocytic leukemia based on expression of the SV40 large T antigen. Blood. 2009; 114(1):119-27. DOI: 10.1182/blood-2009-01-198937. View

15.

Kulis M, Heath S, Bibikova M, Queiros A, Navarro A, Clot G . Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet. 2012; 44(11):1236-42. DOI: 10.1038/ng.2443. View

16.

Fabbri G, Rasi S, Rossi D, Trifonov V, Khiabanian H, Ma J . Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med. 2011; 208(7):1389-401. PMC: 3135373. DOI: 10.1084/jem.20110921. View

17.

Metzker M . Sequencing technologies - the next generation. Nat Rev Genet. 2009; 11(1):31-46. DOI: 10.1038/nrg2626. View

18.

Nehrt N, Peterson T, Park D, Kann M . Domain landscapes of somatic mutations in cancer. BMC Genomics. 2012; 13 Suppl 4:S9. PMC: 3394412. DOI: 10.1186/1471-2164-13-S4-S9. View

19.

Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D . Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011; 365(15):1384-95. PMC: 3322589. DOI: 10.1056/NEJMoa1103283. View

20.

Harris R, Wang T, Coarfa C, Nagarajan R, Hong C, Downey S . Comparison of sequencing-based methods to profile DNA methylation and identification of monoallelic epigenetic modifications. Nat Biotechnol. 2010; 28(10):1097-105. PMC: 2955169. DOI: 10.1038/nbt.1682. View